DUBLIN--ICON plc, (NASDAQ: ICLR) a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today launched ICONIK Patient Safety, the latest service to leverage its ICONIK technology platform.
Identifying potentially significant clinical issues in real-time, ICONIK Patient Safety offers a systematic way to monitor safety trends in accumulating data, spot potential safety issues and take appropriate corrective and preventative action while the study is on-going. Data can be queried dynamically at any level of detail (single patient, single site, across an entire study or entire compound), helping sponsors make informed, data driven decisions regarding patient treatment and safety, study direction and regulatory reporting. ICONIK Patient Safety eliminates the lengthy, manual review of individual patient files, allowing a faster and easier review of aggregated safety events across study populations.
Commenting on the new service, Dr. Peter Schueler, Senior Vice President Medical & Safety Services, ICON Clinical Research, said: "Patient wellbeing is paramount in any clinical trial. ICONIK Patient Safety allows real-time review of integrated patient safety data, thereby improving our ability to identify and monitor unexpected adverse events. ICONIK Patient Safety helps study teams maintain a view of a drug's evolving safety profile by accumulating safety data in real-time and allowing for quick identification of emerging safety issues, affording greater protection of patients' well-being. Before ICONIK Patient Safety, this level of dynamic analysis and management of patient safety was simply not possible."
ICONIK Patient Safety is the latest service to leverage the ICONIK technology platform and follows ICON's recent announcement of ICONIK Monitoring, a new service that improves quality and reduces the costs of clinical development through more effective use of monitoring resources.
The statements made in this press release may contain forward-looking statements that involve a number of risks and uncertainties. A description of risks and uncertainties relating to ICON and its business can be found in Forms 20-F for the fiscal year ended December 31st 2012 and in the other forms filed with the US Securities and Exchange Commission, including the F-1, S-8 and F-3. ICON disclaims any intent or obligation to update these forward-looking statements.
About ICON plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has approximately 10,170 employees, operating from 78 locations in 37 countries.